Viking Therapeutics Announces Completion of Enrollment in Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
- Monday, January 9, 2023, 7:13
- PR Newswire
- Add a comment
Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating Range of VK2809 Doses for up to 52 Weeks; Data for Primary Endpoint Expected in First Half of 2023 SAN DIEGO, Jan. 9, 2023 /PRNewswire/ — Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage…
About the Author
admin has written 20972 stories on this site.